» Articles » PMID: 34744048

Pedunculopontine and Cuneiform Nuclei Deep Brain Stimulation for Severe Gait and Balance Disorders in Parkinson's Disease: Interim Results from a Randomized Double-Blind Clinical Trial

Abstract

Background: Dopa-resistant freezing of gait (FOG) and falls represent the dominant motor disabilities in advanced Parkinson's disease (PD).

Objective: We investigate the effects of deep brain stimulation (DBS) of the mesencephalic locomotor region (MLR), comprised of the pedunculopontine (PPN) and cuneiform (CuN) nuclei, for treating gait and balance disorders, in a randomized double-blind cross-over trial.

Methods: Six PD patients with dopa-resistant FOG and/or falls were operated for MLR-DBS. Patients received three DBS conditions, PPN, CuN, or Sham, in a randomized order for 2-months each, followed by an open-label phase. The primary outcome was the change in anteroposterior anticipatory-postural-adjustments (APAs) during gait initiation on a force platformResults:The anteroposterior APAs were not significantly different between the DBS conditions (median displacement [1st-3rd quartile] of 3.07 [3.12-4.62] cm with sham-DBS, 1.95 [2.29-3.85] cm with PPN-DBS and 2.78 [1.66-4.04] cm with CuN-DBS; p = 0.25). Step length and velocity were significantly higher with CuN-DBS vs. both sham-DBS and PPN-DBS. Conversely, step length and velocity were lower with PPN-DBS vs. sham-DBS, with greater double stance and gait initiation durations. One year after surgery, step length was significantly lower with PPN-DBS vs. inclusion. We did not find any significant change in clinical scales between DBS conditions or one year after surgery.

Conclusion: Two months of PPN-DBS or CuN-DBS does not effectively improve clinically dopa-resistant gait and balance disorders in PD patients.

Citing Articles

Modulating the cholinergic system-Novel targets for deep brain stimulation in Parkinson's disease.

Witzig V, Pjontek R, Tan S, Schulz J, Holtbernd F J Neurochem. 2024; 169(2):e16264.

PMID: 39556446 PMC: 11808463. DOI: 10.1111/jnc.16264.


A framework for translational therapy development in deep brain stimulation.

Chen J, Chen J, Volkmann J, Ip C NPJ Parkinsons Dis. 2024; 10(1):216.

PMID: 39516465 PMC: 11549317. DOI: 10.1038/s41531-024-00829-5.


Directional Subthalamic Deep Brain Stimulation Better Improves Gait and Balance Disorders in Parkinson's Disease Patients: A Randomized Controlled Study.

Cherif S, Tempier N, Yeche M, Temiz G, Perriere J, Romanato M Ann Neurol. 2024; .

PMID: 39475137 PMC: 11683173. DOI: 10.1002/ana.27099.


Cholinergic nucleus degeneration and its association with gait impairment in Parkinson's disease.

Zhang X, Wang M, Lee S, Yue Y, Chen Z, Zhang Y J Neuroeng Rehabil. 2024; 21(1):120.

PMID: 39026279 PMC: 11256459. DOI: 10.1186/s12984-024-01417-7.


Clinical neurophysiology in the treatment of movement disorders: IFCN handbook chapter.

Lefaucheur J, Moro E, Shirota Y, Ugawa Y, Grippe T, Chen R Clin Neurophysiol. 2024; 164:57-99.

PMID: 38852434 PMC: 11418354. DOI: 10.1016/j.clinph.2024.05.007.